Adverse drug reactions to fluoroquinolone antibiotics - Analysis of reports received in a tertiary care hospital

International Journal of Risk and Safety in Medicine

Volumn 20, Issue 3, 2008, Pages 169-180

  Jose, Jimmy ^a,b   Rao, Padma G M ^a   Jimmy, Beena ^a  

^a MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES   (India)

^b KASTURBA HOSPITAL   (India)

Author keywords

Adverse drug reactions; Fluoroquinolones; Hospital; Spontaneous reports

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; ADVERSE OUTCOME; AGED; AGITATION; ANAPHYLAXIS; ARTICLE; ATAXIA; CHILD; CONFUSION; CONTROLLED STUDY; CONVULSION; DISEASE PREDISPOSITION; DRUG INFORMATION; DRUG SCREENING; FEMALE; HUMAN; INDIA; INFANT; INSOMNIA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NEPHROTOXICITY; PSYCHOSIS; RASH; SIDE EFFECT; SKIN DISCOLORATION; SKIN DISEASE; TEACHING HOSPITAL; TERTIARY HEALTH CARE; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; URTICARIA; VOMITING;

EID: 50249125239     PISSN: 09246479     EISSN: None     Source Type: Journal    
DOI: 10.3233/JRS-2008-0441     Document Type: Article

References (55)

1. A. Alvarez-Requejo, A. Carvajal, B. Begaud, Y. Moride, T. Vega and L.H. Martin Arias, Under reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system, Eur. J. Clin. Pharmacol. 54 (1998), 483-488.
2. P. Ball, Adverse drug reactions: implications for the development of fluoroquinolones, J. Antimicrob. Chemother. 51 (2003), 21-27.
3. P. Ball, L. Mandell, Y. Niki and G. Tillotson, Comparative tolerability of the newer fluoroquinolone antibacterials, Drug Saf. 21 (1999), 407-421.
4. P. Ball and G. Tillotson, Tolerability of fluoroquinolone antibiotics: past, present and future, Drug Saf. 13 (1995), 343-358.
5. D.W. Bates, L.L. Leape and S. Petrycki, Incidence and preventability of adverse drug events in hospitalized adults, J. Gen. Intern. Med. 8 (1993), 289-294.
6. J. Bertino and D. Fish, The safety profile of the fluoroquinolones, Clin. Ther. 22 (2000), 798-817.
7. M.D. Blum, D.J. Graham and C.A. McCloskey, Temafloxacin syndrome: review of 95 cases, Clin. Infect. Dis. 18 (1994), 946-950.
8. Bristol-Myers Squibb, Tequin (gatifloxacin) prescribing information (revised), Princeton, NJ, 2006.
9. A. De Sarro and G. De Sarro, Adverse reactions to fluoroquinolones. An overview on mechanistic aspects, Curr. Med. Chem. 8 (2001), 371-384.
10. A. Doussau de Bazignan, F. Thiessard, G. Miremont-Salame, C. Conri and F. Haramburu, Psychiatric adverse effects of fluoroquinolones: review of cases from the French pharmacologic surveillance database, Rev. Med. Intern. 27 (2006), 448-452.
11. I.R. Edwards, Pharmacological basis of adverse drug reactions, in: Avery's Drug Treatment, N.H.G. Holford and T.M. Speight, eds, Adis International, Auckland, 1997, pp. 261-299.
12. I.R. Edwards, Spontaneous reporting of what? Clinical concerns of drugs, Br. J. Clin. Pharmacol. 48 (1999), 138-141.
13. European commission, A guideline on summary of product characteristics, October 2005, http://pharmacos.eudra.org/F2/eudralex/vol-2/C/SPCGuidRev0-Dec99. pdf.
14. R.S. Evans, J.F. Lloyd, G.J. Stoddard, J.R. Neberker and M.H. Samore, Risk factors for adverse drug events: A 10 year analysis, Ann. Pharmacother. 39 (2005), 1161-1168.
15. T.S. Field, J.H. Gurwitz, J. Avorn, D. McCormick, S. Jain and M. Eckier, Risk factors for adverse drug events among nursing home residents, Arch. Intern. Med. 161 (2001), 1629-1634.
16. D.N. Fish, Fluoroquinolone adverse effects and drug interactions, Pharmacotherapy 21 (2001), 253S-272S.
17. E.B. Fonescue, R. Kausbal, C.P. Landrigan, K.J. McKenna, M.D. Clapp and F. Federico, Prioritizing strategies for preventing medication errors and adverse drug events in pediatric inpatients, Pediatrics 111 (2003), 722-729.
18. Food and Drug Administration Center for Drug Evaluation and Research, Approved Drugs Products with Therapeutic Equivalence Evaluations, 25th edn, US Food and Drug Administration, Bethesda, MD, 2005.
19. L. Galatti, S.E. Giustini, A. Sessa, G. Polimeni, F. Salvo, E. Spina and A.P. Caputi, Neuropsychiatric reactions to drugs: an analysis of spontaneous reports from general practitioners in Italy, Pharmacol. Res. 51 (2005), 211-216.
20. L. Gallelli, G. Ferreri, M. Colosimo, D. Pirritano, M.A. Flocco and G. Pelaia, Retrospective analysis of adverse drug reactions to bronchodilators observed in two pulmonary divisions of Catanzaro, Italy, Pharmacol. Res. 47 (2003), 493-499.
21. L. Gallelli, G. Ferreri, M. Colosimo, D. Pirritano, L. Guadagnino and G. Pelaia, Adverse drug reactions to antibiotics observed in two pulmonology divisions of Catanzaro, Italy, A six year retrospective study, Pharmacol. Res. 46 (2002), 395-400.
22. T.K. Gandhi, S.N. Weingart, J. Borus, A.C. Seger, J. Peterson and E. Burdick, Adverse drug events in ambulatory care, N. Eng. J. Med. 348 (2003), 1156-1164.
23. G. Gonzalez-Martin, C.M. Caroca and E. Paris, Adverse drug reactions (ADRs) in hospitalized pediatric patients-a prospective study, Int. J. Clin. Pharmacol. Ther. 36 (1998), 530-533.
24. J. Hallgren, M. Tengvall-Linder, M. Persson and C.F. Wahlgren, Steven-Johnson syndrome associated with ciprofloxacin: a review of adverse cutaneous events reported in Sweden as associated with this drug, J. Am. Acad. Dermatol. 49 (2003), S267-S269.
25. S.C. Hartwig, J. Siegel and P.J. Schneider, Preventability and severity assessment in reporting adverse drug reactions, Am. J. Hosp. Pharm. 49 (1992), 2229-2232.
26. Health Canada, Advisory: Health Canada advises diabetic patients not to use the antibiotic Tequin, www.hc-sc.gc.ca/ahcasc/media/advisories-avis/2006/ 2006_09_e.html (accessed December 17, 2006).
27. E.F. Hendeshot, Fluoroquinolones, Infect. Dis. Clin. North Am. 9 (1995), 715-730.
28. P. Kanjanarat, A.G. Winterstein, T.E. Johns, R.C. Hatton, R. Gonzalez-Rothi and R. Segal, Nature of preventable adverse drug events in hospitals: A literature review, Am. J. Health Syst. Pharm. 60 (2003), 1750-1759.
29. S.C. Karande and N.A. Kshirsagar, Adverse drug reaction monitoring of ciprofloxacin in pediatric practice, Ind. Pediatr. 29 (1992), 181-188.
30. P.M. Lau, K. Stewart and M.J. Dooley, Comment: hospital admissions resulting from preventable adverse drug reactions, Ann. Pharmacother. 37 (2003), 303-304.
31. R. Leone, M. Venegoni, D. Motola, U. Moretti, V. Piazzetta, A. Cocci, D. Resi, F. Mozzo, G. Velo, L. Burzilleri, N. Montanaro and A. Conforti, Adverse drug reactions related to the use of fluoroquinolone antimicrobials - An analysis of spontaneous reports and fluoroquinolone consumption data from three Italian regions, Drug Saf. 26 (2003), 109-120.
32. J.A. Linder, E.S. Huang, M.A. Steinman, R. Gonzales and R.S. Stafford, Fluoroquinolone prescribing in the United States: 1995 to 2002, Am. J. Med. 118 (2005), 259-268.
33. B.M. Lomaestro, Fluoroquinolone induced renal failure, Drug Saf. 22 (2000), 479-485.
34. R.H.B. Meyboom, A.C.G. Egberts, I.R. Edwards et al., Principles of signal detection in pharmacovigilance, Drug Saf. 16 (1997), 355-365.
35. Y. Moride, F. Haramburu, A.A. Requeyo and B. Begaud, Underreporting of adverse drug reactions in general practice, Br. J. Clin. Pharmacol. 43 (1997), 177-181.
36. C.A. Naranjo, U. Busto, E.M. Sellers, P. Sandor, I. Ruiz and E.A. Roberts, A method for estimating the probability of adverse drug reactions, Clin. Pharmacol. Ther. 30 (1981), 239-245.
37. L.E. Nicolle, Fluoroquinolones in the aged, Drugs 58 (1999), 49-51.
38. R.C. Owens Jr., QT prolongation with antimicrobial agents: understanding the significance, Drugs 64 (2004), 1091-1124.
39. G. Parthasarathi and S. Olsson, Adverse drug reactions, in: A Text Book of Clinical Pharmacy Practice-Essential Concepts and Skills, G. Parthasarathi, K. Nyfort-Hansen and M.C. Nahata, eds, Orient Longman Pvt. Ltd., Chennai, 2004, pp. 86-102.
40. Prod Information, Levaquin (R) tablets, oral solution, injection, Ortho-McNeil Pharmaceuticals, Inc., Raritan, NJ, 2004.
41. M.D. Rawlins and J.W. Thompson, Pathogenesis of adverse drug reactions, in: Textbook of Adverse Drug Reactions, D.M. Davies, ed., Oxford University Press, Oxford, 1977, p. 44.
42. K. Reeta, R. Uppal, R. Jhaj, S. Malhotra and V.K. Bhargava, Adverse drug reactions to fluoroquinolones in pediatric patients in a tertiary care hospital, Ind. J. Physiol. Pharmacol. 44 (2000), 113-114.
43. B. Regal, Finally a pharmacovigilant India, Uppsala Rep. 25 (2004), 7-8.
44. E. Rubinstein, History of quinolones and their side effects, Chemotherapy 47 (2001), 3-8.
45. B. Sachs, S. Riegel, J. Seebeck, R. Beier, D. Schichler, A. Barger, H.F. Merk and S. Erdmann, Fluoroquinolone-associated anaphylaxis in spontaneous adverse reaction reports in Germany: differences in reporting rates between individual fluoroquinolones and occurrence after first ever use, Drug Saf. 29 (2006), 1087-1090.
46. A.J. Schaeffer, The expanding role of fluoroquinolones, Am. J. Med. 113 (2002), 45S-54S.
47. G. Schluter, Ciprofloxacin: review of potential toxicological effects, Am. J. Med. 82(Suppl. 4A) (1987), 91-93.
48. K.A. Sprandel and K.A. Rodvold, Safety and tolerability of fluoroquinolones, Clin. Cornerston Supl. 3 (2003), S29-S36.
49. R. Stahlmann and H. Lode, Fluoroquinolone in the elderly: safety considerations, Drugs Aging 20 (2003), 289-302.
50. B.L. Storm, What is pharmacoepidemiology?, in: Pharmacoepidemiology, Wiley, Chichester, 2000, pp. 3-15.
51. D.C. Suh, B.S. Woodall, S.K. Shin and E.R. Hermes-De-Santis, Clinical and economic impact of adverse drug reactions in hospitalized patients, Ann. Pharmacother. 34 (2000), 1373-1379.
52. R. Uppal, R. Jhaj and S. Malhotra, Adverse drug reactions to fluoroquinolones at a tertiary care teaching hospital in northern India, J. Assoc. Phys. India 46 (1998), 946-947.
53. P.D. Van der Linden, M.C. Sturkenboom, R.M. Herings, H.G. Leufkens and B.H. Stricker, Fluoroquinolones and risk of Achilles tendon disorders: case control study, BMJ 324 (2002), 1304-1307.
54. L.J.G. Veehof, R.E. Stewart, F.M. Haaijer-Ruskamp and B. Meyboom-de Jong, The development of polypharmacy. A longitudinal study, Family Practice 17 (2000), 261-267.
55. WHO-Uppsala Monitoring Center, WHO Adverse reaction terminology, 2003.